Earn CME: https://naccme.com/program/7329
In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Prashant Kapoor agues that MRD should be the treatment target for patients with multiple myeloma.
© 2019 Imedex, an HMP Company